洛铂与复方苦参注射液联合腹腔灌注治疗卵巢癌并发恶性腹水的疗效及其对肿瘤坏死因子的影响  

Therapeutic effect of losecplatin combined with compound matrine in the intraperitoneal perfusion treatment of ovarian cancer with malignant ascites and its effect on TNF

作　　者：张涛[1] 徐海亭[1] 惠华[1] 耿冲[1] 丁曼华[1] 许晶[1] 

机构地区：[1]江苏大学附属徐州医院放疗科,江苏省徐州221000

出　　处：《中国基层医药》2017年第15期2281-2284,共4页Chinese Journal of Primary Medicine and Pharmacy

基　　金：江苏大学医学临床科技发展基金（JLY20160069）

摘　　要：目的 评估洛铂与复方苦参注射液联合腹腔灌注治疗卵巢癌并发恶性腹水的短期效果及其对肿瘤坏死因子（TNF）的影响.方法 将60例确诊为卵巢癌并发恶性腹水的患者按随机数字表法分为三组：洛铂联合复方苦参注射液灌注组（联合组）、洛铂单药灌注组（洛铂组）及复方苦参注射液单药灌注组（复方苦参组）,每组20例.三组均置中心静脉导管于腹腔内以便引流积液及药物灌注,治疗前开始前三组均排尽腹腔内的积液,之后按照上述分组行腹腔灌注治疗.比较三组治疗效果、副反应以及对血清TNF水平的影响.结果 三组患者均顺利完成治疗,联合组有效率为95%,洛铂组为60%,复方苦参组为55%,联合组有效率明显优于单药组（χ^2=7.025,P〈0.05）,且不良反应较单药组无明显增加（χ^2=1.026,P〉0.05）;三组灌注治疗后的血清TNF水平均明显低于治疗前（t=15.40、13.82、8.90,均P〈0.05）,且联合组TNF水平降低更明显,差异有统计学意义（F=9.719,P〈0.05）.结论 洛铂与复方苦参注射液联合腹腔灌注是一种更加有效的治疗卵巢癌并发恶性腹水的方法,临床值得推荐.Objective To evaluate the effect of losecplatin combined with compound matrine in the intraperitoneal perfusion treatment of ovarian cancer with malignant ascites and its influence on the levle of serum tumor necrosis factor alpha（TNF-） of ovarian cancer marker.Methods 60 ovarian cancer patients with malignant ascites were divided into three groups：losecplatin combined with compound matrine perfusion group（combination group）,single losecplatin perfusion group（losecplatin group） and single compound matrine perfusion group（compound matrine group）,20 cases in each group.Before treatment,all the three groups were drained intraperitoneal fluid,then given the above-mentioned group of intraperitoneal perfusion therapy.The effects,side effects and serum TNF- levels of the three groups were compared.Results The patients of the three groups were successfully completed treatment,the effective rate of the combination group was 95%,which of the losecplatin group was 60%,which of the compound matrine group was 55%.The effective rate of the combination group was significantly higher than that of the single drug group（χ^2=7.025,P〈0.05）,and the adverse reaction of the combination group was not significantly increased（χ^2=1.026,P〉0.05）.The serum TNF- levels of the three groups after the perfusion treatment were significantly decreased（t=15.40,13.82,8.90,all P〈0.05）,TNF- level of the combination group was significantly lower,the difference was statistically significant（F=9.719,P〈0.05）.Conclusion Losecplatin combined with compound matrine in the intraperitoneal perfusion is a more effective method for the treatment of ovarian cancer with malignant ascites,which is worthy of promotion.

关 键 词：卵巢肿瘤 腹水 细胞因子类 洛铂 复发苦参注射液 

分 类 号：R737.31[医药卫生—肿瘤]